~"iorrenr ~ PHRRmR

!81h .January, 2018 ~ Dy. General Manager (Listing Dept.) The Manager·- Listin ept., BSE Lnntted., National Stock Ex ange of Ltd., Corporate Relationship Dept., Exchange Pia- , 51h Floor, I st Floor, New Trading Ring, Plot No.. , G. Block, P . .1. Towers, Dalal Street, Fort, Band· - Kurla Complex, Bandra (E), Mumbai- 400 00 I mbai -- 400 051 (BSE Scrip Code: 500420) (NSE Scrip Code: TORNTPHARM) Dear Sir,

Sub.: Press Release- Torrent }>harm a acquires Bio-Pharm Inc.

We would like to inform you that Limited, through its wholly owned subsidiary Torrent Pharma Inc., has acquired Bio-Pharm Inc., a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA.

A press release with respect to the above matter is enclosed herewith for your information and records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED

MAHESH AGRAWAL VP (LEGAL) & COMPANY SECRETARY

Encl: As above

TORRENT PHARMACEUTICALS LIMITED C!N: L24230GJ1972PLC002126 Reg.Office: Torrent House, Off Ashram Road, . 380 009, India. Phone: +91 79 26599000, Fax: +91 79 26582100, www.torrentpharma.com Torrent Pharma acquires Bio-Phann, Inc.

Ahmedabad, 18'" .January, 2018: Torrent Pharmaceuticals Limited ("Torrent") today, announced the acquisition of Bio-Pharm, Inc. (BPI) a generic pharmaceuticals and OTC Company, based in Levittown Pennsylvania, USA. ·

Established in 1992, BPI has a proven track record in the research & development and manufacturing of oral solutions, suspensions and suppositories. Its 75,000 sq. ft US FDA registered facility has manufacturing capabilities for controlled substances which can be manufactured in US only as per Government guidelines (DEA Schedule 11-V). To date, BPI has 10 approved AND As, 10 AND As under review at the FDA for itself and it's partners and has an additional 17 products under development. Torrent plans further investments to expand the BPI facilities including R&D capabilities and will increase the number of product filings from BPI.

This acquisition is an important step for increasing Torrent's presence in the United States, is consistent with our strategy of dosage form diversification, and provides us with new capabilities including manufacturing and R&D presence in the USA.

About Torrent Pharma

Torrent Phanna, with annual revenues of more than Rs. 5800 crores is the flagship Company of the Rs. 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefi·ont of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AJOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for ·both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, , Dahej, Pithampur and Vizag have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.